IR@PKUHSC  > 北京大学精神卫生研究所
学科主题精神卫生
Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, flxed-dose, parallel trial in a Chinese population
Mao, Pei-xian1; Tang, Yi-lang1,3; Jiang, Feng1; Shu, Liang4; Gu, Xiuling5; Li, Ming6; Qian, Mincai7; Ma, Cui8; Mitchell, Philip B.9; Cai, Zhuo-ji1
关键词Major Depressive Disorder Antidepressant Escitalopram Fluoxetine Efficacy Ham-d-17 Madrs Chinese Race
刊名DEPRESSION AND ANXIETY
2008
DOI10.1002/da.20222
25期:1页:46-54
收录类别SCI ; SSCI
文章类型Article
WOS标题词Social Sciences ; Science & Technology
类目[WOS]Psychology, Clinical ; Psychiatry ; Psychology
研究领域[WOS]Psychology ; Psychiatry
关键词[WOS]PRIMARY-CARE PATIENTS ; CLINICAL-PRACTICE ; ELDERLY-PATIENTS ; POOLED ANALYSIS ; R-ENANTIOMER ; 10 MG/DAY ; CITALOPRAM ; EFFICACY ; PLACEBO ; ANTIDEPRESSANT
英文摘要

Escitalopram, the S-enantiomer of citalopram and the most selective of the selective serotonin reuptake inhibitor (SSRI) has been shown to be efficacious in the treatment of major depression in white populations. Our aim in this study was to investigate the efficacy and tolerability of escitalopram in Chinese patients with moderate to severe major depression. Patients who met DSM-IV criteria for a major depressive episode were enrolled in this multicenter randomized, double-blind, fixed-dose comparison trial. Patients were given escitalopram 10 mg/day or fluoxetine 20 mg/day for 8 weeks. All patients were assessed with the 17-item Hamilton Depression Rating Scale (HAM-D-17) and the Montgomery-(a) over circle sberg Depression Rating Scale (MADRS). Tolerability was assessed on the basis of adverse effects (measured with a locally developed checklist), regular biochemical tests, and electrocardiograph (ECG) assessments. Two hundred forty patients were enrolled and randomized to escitalopram (123 patients) or fluoxetine (117 patients). The HAM-D-17 total scores of both groups decreased significantly from baseline, but there was no significant difference at week 8 between the two groups (15.8 for escitalopram and 14.7 for fluoxetine; P >.05). There were no significant differences in response rates at all visits after treatment based on either HAM-D-17 or MADRS. A post hoc analysis indicated that escitalopram was superior to fluoxetine on two items of the HAM-D-17. "depressed mood" (P=.023) and "work and interest" (P =. 024). The adverse events reported in the escitalopram and fluoxetine groups were comparable, and most were mild to moderate. Both drugs showed good compliance profiles. Escitalopram 10 mg/day is at least as efficacious as fluoxetine 20 mg/day and well tolerated in Chinese patients with major depression, with possible superiority in some core symptoms such as "depressed mood" and "work and interest.".

语种英语
WOS记录号WOS:000252871500006
引用统计
被引频次:21[WOS]   [WOS记录]     [WOS相关记录]
文献类型期刊论文
条目标识符http://ir.bjmu.edu.cn/handle/400002259/51334
专题北京大学精神卫生研究所
作者单位1.Emory Univ, Dept Human Genet, Atlanta, GA 30322 USA
2.Emory Univ, Dept Psychiat & Behav Sci, Atlanta, GA 30322 USA
3.Peking Univ, Mental Hlth Inst, Beijing 100871, Peoples R China
4.Suzhou Guangji Hosp, Suzhou, Jiansu Province, Peoples R China
5.Huzhou Mental Hlth Ctr, Huzhou, Zhejiang Prov, Peoples R China
6.Guangzhou Brain Hosp, Guangzhou, Guangdong, Peoples R China
7.Capital Univ Med Sci, Beijing Anding Hosp, Beijing 100088, Peoples R China
8.Capital Univ Med Sci, Beijing Chaoyang Hosp, Beijing 100088, Peoples R China
9.Univ New S Wales, Sch Psychiat, Kensington, NSW 2033, Australia
推荐引用方式
GB/T 7714
Mao, Pei-xian,Tang, Yi-lang,Jiang, Feng,et al. Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, flxed-dose, parallel trial in a Chinese population[J]. DEPRESSION AND ANXIETY,2008,25(1):46-54.
APA Mao, Pei-xian.,Tang, Yi-lang.,Jiang, Feng.,Shu, Liang.,Gu, Xiuling.,...&Cai, Zhuo-ji.(2008).Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, flxed-dose, parallel trial in a Chinese population.DEPRESSION AND ANXIETY,25(1),46-54.
MLA Mao, Pei-xian,et al."Escitalopram in major depressive disorder: A multicenter, randomized, double-blind, flxed-dose, parallel trial in a Chinese population".DEPRESSION AND ANXIETY 25.1(2008):46-54.
条目包含的文件
条目无相关文件。
个性服务
推荐该条目
保存到收藏夹
查看访问统计
导出为Endnote文件
谷歌学术
谷歌学术中相似的文章
[Mao, Pei-xian]的文章
[Tang, Yi-lang]的文章
[Jiang, Feng]的文章
百度学术
百度学术中相似的文章
[Mao, Pei-xian]的文章
[Tang, Yi-lang]的文章
[Jiang, Feng]的文章
必应学术
必应学术中相似的文章
[Mao, Pei-xian]的文章
[Tang, Yi-lang]的文章
[Jiang, Feng]的文章
相关权益政策
暂无数据
收藏/分享
所有评论 (0)
暂无评论
 

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。